SPMDvsXBI
SPDR Portfolio S&P 400 Mid Cap ETF against SPDR S&P Biotech ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| SPMD | XBI | |
|---|---|---|
| Expense ratio | 0.030% | 0.35% |
| Assets | $17.9B | $10.4B |
| Net flow, 1 month | +$207M | −$690M |
| Net flow, 1 year | +$2.1B | +$1.1B |
| Return, YTD | +10.0% | +26.7% |
| Return, 1 year | +11.0% | +52.4% |
| Avg daily volume | 1.5M | 8.6M |
| Holdings | 401 | 135 |
| Listed | Nov 8, 2005 | Jan 31, 2006 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS